Institutional Investors' Divergent Views on Pfizer Stock

2024-03-12

During the meeting held to discuss Pfizer's performance in the quarter ending December 31, 2023, it was revealed that the company is a significant holding for both hedge funds and ETFs. The data presented indicated that there are 2,796 hedge funds collectively holding 4,009,809,698 shares of Pfizer, while ETFs hold 56 funds with a total of 262,782,313 shares. Among the top institutional holders of Pfizer are Vanguard Group Inc., BlackRock Inc., and State Street Corp.

In the last quarter, 933 hedge funds were actively buying Pfizer shares, while 1,591 were selling off their holdings. The total number of shares bought amounted to 229,792,791, whereas 260,991,329 shares were sold. Notably, 123 hedge funds doubled their position on Pfizer, while 27 funds decided to divest at least 90% of their shares.

The meeting also highlighted the sentiment of various institutions towards Pfizer, with some expressing optimism and others a more pessimistic view. Among the most optimistic institutions were Susquehanna International Group, LLP, and Norges Bank, while Capital World Investors and Two Sigma Advisers, LP, were noted as being among the most pessimistic.

The data presented during the meeting was sourced from sharkstracker.com, providing a data-driven perspective on the market dynamics surrounding Pfizer. For those interested in a more comprehensive analysis, the full report can be accessed for purchase through the following link: [SharksTracker Pfizer Report](https://www.sharkstracker.com/reports/ReportDetail12:PFE/?rrr=3).